Mekophar's 2026 AGM to Unveil Growth Plans and Dividend Policy

Mekophar Chemical Pharmaceutical will hold its Annual General Meeting (AGM) on March 18, 2026. Shareholders will review the company's financial performance and discuss future strategies, including dividend policies and key investment projects.

Over the past five years, Mekophar has expanded its presence in Vietnam's pharmaceutical market. Its market share grew from 1.5% in 2021 to 2.8% in 2025, driven by increased production capacity and new product launches in generics and over-the-counter drugs. Revenue also rose from VND 1,200 billion to VND 2,100 billion during this period, according to company reports and industry analyses.

At the AGM, management will present detailed financial results for the last fiscal year. Shareholders will vote on profit allocation and examine the progress of the 'Mekophar Bio-Pharmaceutical Research, Development, and Production Investment Project.' This initiative remains a key focus, with investors seeking updates on regulatory milestones and pipeline advancements. The meeting will also address the company's strategic priorities for the coming years. With growing market demand, management has emphasised the need to align future products accordingly. Shareholders registered by March 18 will be eligible to attend and influence decisions on the group's direction.

The AGM will provide clarity on Mekophar's dividend policy and investment plans. Shareholders will have the chance to shape the company's future, with discussions centred on financial performance and long-term growth strategies. Decisions made at the meeting will guide the firm's next steps in Vietnam's competitive pharmaceutical sector.